Sélectionner une page
Logo Company

Enyo Pharma

Tatiana DANTHENY

CEO Project Assistant

Who are we?

ENYO PHARMA is a biopharmaceutical company which has developed an innovative drug discovery engine inspired by viruses to identify first-in-class chemistries. The key of this approach based on biomimetism is to identify the right protein-protein interactions (PPIs) to mimic the virus strategy. Our main candidate EYP001 is an FXR agonist about to enter phase 2 for both HBV and NASH. Our second candidate, EYP002, is currently in preclinic. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO to explore new indications such as oncology and metabolic diseases. The company has also received funding from the EU H2020 programme for its MIMESIS project, to scale-up its drug discovery engine in various therapeutic areas following the successful proof-of-concept with EYP002.